PULMONARY ARTERIAL HYPERTENSION DRUG MARKET ANALYSIS

Pulmonary Hypertension (PH) is a rare disease that affects the pulmonary arteries. High blood pressure in the lungs is called pulmonary arterial hypertension (PAH) or pulmonary hypertension (PH). It is characterized by narrowed and blocked arteries and capillaries. This rare disease usually worsens over time and can lead to death if left untreated. Due to the increase in the incidence of PAH (pulmonary arterial hypertension), the increase in the geriatric population, and the increasing government support for the development of orphan drugs, the market is expected to witness significant growth during the forecast period.

The global pulmonary arterial hypertension drug market is estimated to be valued at US$ 7,310.1 Million in 2022 and is expected to reach US$ 11,220.2 million by 2030, at a CAGR of 5.5% during the forecast period (2022–2030).

Figure 1. Global Pulmonary Arterial Hypertension Drug Market Share (%), By Region, 2022

To learn more about this report, request a free sample copy

An increasing number of heart failure causes pulmonary arterial hypertension (PH) cases, which is expected to increase significantly during the forecast period.

The pulmonary arterial hypertension drug market is expected to see significant growth during the forecast period as the number of heart failures continues to rise, which then leads to cases of pulmonary arterial hypertension (PAH). For instance, in 2019, Heart Failure Society of America reported that there are approximately 550,000 newly diagnosed heart failure cases in the U.S. each year, and nearly 1.4 million congestive heart failure (CHF) patients are under 60 years of age.

Figure 2. Global Pulmonary Arterial Hypertension Drug Market Share, By Drug Class, 2022

To learn more about this report, request a free sample copy

Increasing collaboration for the development of novel products is expected to drive growth of pulmonary arterial hypertension drug market over the forecast period.

Key players are focusing on collaborations and mergers to develop new products for the pulmonary arterial hypertension (PAH) market, which is expected to promote pulmonary arterial hypertension drug market growth during the forecast period. For example, in 2017, Bayer AG, a German multinational pharmaceutical and Life Sciences Company and Vectura Group Plc., a British pharmaceuticals business, expanded their collaboration to develop an improved version of the Breelib nebulizer, which improves the efficacy of iloprost aerosol in the treatment of pulmonary atrial hypertension.

Global Pulmonary Arterial Hypertension Drug Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency in 2020. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally as of August 9, 2022, are approximately 583,038,110 confirmed cases with 6,416,023 deaths. The Coronavirus (COVID-19) outbreak started from Wuhan, China and has spread across continents, affecting various industries globally.

Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, U.A.E., Egypt, and others are facing problems with regards to transportation of drugs from one place to another. However, the crisis due to coronavirus disease has given a boost to pharmaceutical companies to grow and develop an ambitious drug and vaccine projects with a sole aim to contain the viral outbreak. Such demanding R&D projects are in turn creating a wealth of opportunities for innovations in global pulmonary arterial hypertension drug market.

Global Pulmonary Arterial Hypertension Drug Market: Restraint

Factors such as expiration of key molecule patents, drug-related side effects such as gastric ulcers, hypotension, congestive heart failure, lack of awareness among people in emerging countries such as India Brazil, China and others, and high costs of diagnosis and treatment are expected to hamper the global pulmonary arterial hypertension drug market growth.

Key Players

Major players operating in the global pulmonary arterial hypertension drug market include United Therapeutics Corporation, GlaxoSmithKline plc., Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Daiichi Sankyo Company, Limited, Sandoz AG, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd. and Mylan N.V.